On the Ground and In the Cloud: A Deep Dive into the Trends Impacting Developer Technologies
Software developers not only represent the early adopters who will determine the success of a particular product or project, but also have become primary influencers in software purchases. In the latest William Blair Thinking Podcast, analysts Jason Ader, Arjun Bhatia, and Jonathan Ho delve into the key trends and potential disruptions, including generative AI, in this exciting new era of coding capabilities.
Listen to the podcast
Themes and Trends on the Rise in Philanthropy
In recognition of Giving Tuesday, we invite you to learn more about the innovative trends shaping the state of charitable giving and how William Blair’s philanthropic services are a significant part of our client engagement; as outlined by our Head of Philanthropy Strategy, Laura Coy.
Watch the video
Biotech Breakthroughs–Exploring the Recent Radiopharmaceutical Renaissance
Radiopharmaceuticals are leading the way in how oncology patients are being diagnosed and treated. In this episode of Biotech Breakthroughs, Tim Lugo is joined by equity analysts Andy Hsieh and Alex Ramsey to examine why radioisotope innovation may revolutionize treatment for millions of people in the coming years.
Listen to the podcast
William Blair Thinking
Cell Therapy and Autoimmune Disorders: Expanding CAR-Ts’ Utility Beyond Oncology
Equity research analysts Sami Corwin and Matt Phipps provide an overview of the known biological underpinnings of autoimmunity and the rationale for using chimeric antigen receptor T cells (CAR-Ts) to potentially treat millions who suffer from autoimmune diseases.
Read more
Did November’s Rally Alter the Market Outlook?
What a difference a month makes. Markets swooned in October, only to see virtually all risk assets, including small-caps, rally in November. What changed? Macro analyst Richard de Chazal breaks down the Fed’s recent statement, the market’s rate expectations, and the current state of the economic slowdown.
Read more
Cosmic Capitalism
The cosmos, the final frontier, the galaxy beyond: Our collective fascination with outer space has always been intense. But with companies and public figures now dedicating huge sums of money to space exploration, it seems a new kind of space race has been born. In this episode of The Active Share, Hugo sits down with Chris Impey, an astronomer, educator, and author, to discuss the potential economic, environmental, and geopolitical ramifications of space exploration.
Listen to the podcastOur Mission, Vision, and Values
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values
Community Engagement at William Blair
"Our job is to bridge the gap between those students who live in underserved communities and the financial industry. What William Blair has done has fully bought into our model of getting to know these young people, understanding their background, and understanding what we are trying to achieve. If not for William Blair, we would not be where we are today.”
Bevon Joseph, Co-Founder of Greenwood Project
Our Latest News
VistaGen Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of VistaGen Therapeutics, Inc. (VTGN $3.65), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other neuropsychiatric disorders.
Read moreFormer U.S. Army Captain Demonstrated ‘Leading with Resilience Through Difficult Times’
Former U.S. Army Captain Wes Becton shared his thoughts on resiliency learned during his military career and what it means during hard times at William Blair’s annual Veterans Day celebration.
Read moreCabaletta Bio, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Cabaletta Bio, Inc. (CABA $13.69), a clinical-stage company focused on the development and commercialization of first-in-class immune cell therapies for the treatment of severe autoimmune disorders.
Read moreJoin Our Team
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search for jobs and apply
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights